These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 526934)
1. Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal Malignancies. DeSimone PA; Greco FA; Lessner HF Cancer Treat Rep; 1979; 63(11-12):2015-7. PubMed ID: 526934 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of anguidine administered weekly. Belt RJ; Haas CD; Joseph U; Goodwin W; Moore D; Hoogstraten B Cancer Treat Rep; 1979; 63(11-12):1993-5. PubMed ID: 526932 [TBL] [Abstract][Full Text] [Related]
3. Phase II evaluation of anguidine (NSC-141537) for adenocarcinoma of the colon or rectum. Diggs CH; Scoltock MJ; Wiernik PH Cancer Clin Trials; 1978; 1(4):297-9. PubMed ID: 757146 [TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of anguidine (diacetoxyscirpenol, NSC-141537). Goodwin W; Haas CD; Fabian C; Heller-Bettinger I; Hoogstraten B Cancer; 1978 Jul; 42(1):23-6. PubMed ID: 667795 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of anguidine in gastrointestinal malignancies: a Southwest Oncology Group study. Bukowski R; Vaughn C; Bottomley R; Chen T Cancer Treat Rep; 1982 Feb; 66(2):381-3. PubMed ID: 7055820 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of anguidine in advanced breast cancer. Yap HY; Murphy WK; DiStefano A; Blumenschein GR; Bodey GP Cancer Treat Rep; 1979 May; 63(5):789-91. PubMed ID: 455316 [TBL] [Abstract][Full Text] [Related]
7. Phase I study on bruceantin administered on a weekly schedule. Liesmann J; Belt RJ; Haas CD; Hoogstraten B Cancer Treat Rep; 1981; 65(9-10):883-5. PubMed ID: 7273023 [TBL] [Abstract][Full Text] [Related]
8. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Löffler TM; Freund W; Lipke J; Hausamen TU Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118 [TBL] [Abstract][Full Text] [Related]
9. Initial clinical studies with bruceantin. Bedikian AY; Valdivieso M; Bodey GP; Murphy WK; Freireich EJ Cancer Treat Rep; 1979; 63(11-12):1843-7. PubMed ID: 526918 [TBL] [Abstract][Full Text] [Related]
10. [The clinical phase I study of TNP-351. The TNP-351 Research Committee]. Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102 [TBL] [Abstract][Full Text] [Related]
11. Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group Trial. DeSimone PA; Greco FA; Lessner HF; Bartolucci A Am J Clin Oncol; 1986 Jun; 9(3):187-8. PubMed ID: 3728370 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of pentamethylmelamine in patients with previously treated malignancies. Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747 [TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha. Greenblatt MS; Mangalik A; Ferguson J; Elias L Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023 [TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic studies of DON. Kovach JS; Eagan RT; Powis G; Rubin J; Creagan ET; Moertel CG Cancer Treat Rep; 1981; 65(11-12):1031-6. PubMed ID: 7296548 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules. Hainsworth JD; Raefsky EL; Greco FA Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of taxol given as a 3-hour infusion every 21 days. Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928 [TBL] [Abstract][Full Text] [Related]